HER-Vaxx Cancer Vaccine Published New Clinical Data

Imugene Limited HER-Vaxx (IMU-131) is a B-cell peptide cancer vaccine designed to treat tumors that over-express the HER-2/neu receptor

HER-Vaxx Cancer Vaccine

An Australian clinical stage immuno-oncology company announced new clinical data from the Phase Ib study of its HER-Vaxx (IMU-131) cancer vaccine candidate, plus chemotherapy.

Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumors that over-express the HER-2/neu receptor, such as gastric cancer.

This new clinical study data is showing HER-Vaxx’s cancer-fighting antibody and clinical response rates continue to be positive in the patients receiving the optimal biological dose of vaccine.

On July 8, 2019, Imugene Limited said in a press release that ‘patients have maintained strong and high levels of HER-2 targeting antibodies indicating a durable response is present, with no resistance developed.’

In this small study, the cohort 3 patients who received the optimal biological dose, and selected Phase 2 dose, have realized positive trends.

One patient has seen a total tumor reduction of almost 80 percent from baseline CT scan, with 1 out of 4 of their lesions becoming unmeasurable by RESIST criteria, on Day 266.

Imugene Managing Director and CEO Leslie Chong said in a press release, “This presentation from the HER-Vaxx Phase 1b study further reinforces the very good early results and ongoing interest among the international oncology community in our potentially promising B-cell platform cancer vaccine and clinical development strategy.”

The Phase 2 study began enrollment in March 2019 and is scheduled to complete in 2020.